@FiercePharma: J&J to pay up to $2.2B in Risperdal settlement, Bloomberg says. Close to Pfizer's record $2.3B deal. More | Follow @FiercePharma
> Now it's generic versions of Pfizer's ($PFE) blockbuster cholesterol pill Lipitor that are seeing sales erosion--from other generics. News
> Roche ($RHHBY) isn't planning to make a second run at Illumina, the gene-sequencing firm it tried to buy earlier this year, and plans to look at smaller deals instead. Report
> Novartis ($NVS) announced new data suggesting that its Gilenya multiple-sclerosis pill was effective at reducing relapses and reducing the loss of brain volume in MS patients, with a "consistent safety profile." Story
> Germany's new drug-pricing system is keeping new medicines out of patients' hands, a European pharma association contends. Item
> Mylan ($MYL) and Teva Pharmaceutical Industries ($TEVA) came to an agreement over generic Provigil, in a deal that allows Mylan to launch its version Aug. 10, before Teva's 180-day exclusivity period expires. Article
> GlaxoSmithKline ($GSK) told the World Anti-Doping Agency that its experimental anti-anemia drug could also be used by athletes as a performance enhancer. More
> Japan's Astellas Pharma launched Dificlir, a treatment for Clostridium dificile infections, in the European market. Report
> Clinigen Group, a U.K.-based drugmaker that licenses pharma's mature or end-of-lifecycle drugs, is looking to sell itself or go public, Sky News reports. News
Biotech News
@FierceBiotech: Merck Serono staffers mull strike as budget ax hovers over Geneva HQ. Item | Follow @FierceBiotech
@JohnCFierce: ADA roundup: J&J's diabetes pioneer edges out Januvia in Phase III. Data looks pretty good, actually. More | Follow @JohnCFierce
@RyanMFierce: Hi all, we're about to launch FierceBiotech's Fierce 15 biotech search. Countdown from 10... Survey | Follow @RyanMFierce
> BioSante preps for two more PhIII LibiGel trials. News
> J&J's diabetes pioneer edges out Januvia in Phase III. More
> Protalix scores $25M milestone from Pfizer. Story
> Roche CEO dashes Illumina from M&A plans. Article
Medical Device News
@FierceMedDev: Get your nominations in for the 15 fiercest private medical device developers while there is still time. Survey | Follow @FierceMedDev
> ECG-maker AliveCor pulls in $10.5M. More
> ConforMIS, an orthopedics implant maker, seeks $68M. Article
> Boston Sci closes $150M deal for Cameron, new ICD. News
> J&J's Animas will advance a second artificial pancreas trial. Story
Biotech IT News
> Biogen vet tapped as CIO of Harvard Med School. News
> Pharma rocks many Twitter handles for many reasons. More
> Novartis predicts drug side effects with computers. Report
> Lilly leads docs to cancer drug trials with iPad app. Item
And Finally... Faced with drug-resistant infections, scientists are looking at reviving a 50-year-old antibiotic despite its risk of kidney damage. Report